Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2012 Oct 30;71(2):331–344. doi: 10.1007/s00280-012-2010-z

Fig. 2.

Fig. 2

Structures and HPLC chromatography of kb-NB142-70 and kb-NB165-09 and their metabolites in plasma. (a) Neat kb-NB142-70 with internal standard (17-allylamino-17-demethoxygeldanamycin, 17-AAG) (b) the chromatogram of kb-NB142-70 added to plasma as a quality control assay standard (c) the chromatogram of kb-NB142-70 and metabolites in plasma obtained 10 min after treating a mouse with 25 mg/kg of kb-NB142-70 iv (d) Structure of kb-NB142-70 (e) Neat kb-NB165-09 with internal standard (17-AAG) (f) Chromatogram of kb-NB165-09 and kb-NB142-70 added to plasma as a quality control assay standard (g) Chromatogram of kb-NB165-09 and metabolites in plasma obtained 10 min after treating a mouse with 25 mg/kg of kb-NB165-09 iv (h) Structure of kb-NB165-09